TY -的T1 Finger-to-nose测试结果在阿尔茨海默氏症(P6.071) JF -神经学乔-神经学六世- 88 - 16补充SP - P6.071 A首页U -大卫Bergeron盟-安东尼Vermette AU -贾斯汀De La Sablonniere盟anne - marie礁盟——罗伯特•Laforce Jr . AU -雷米w·布沙尔Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P6.071.abstract N2 -目的:描述Finger-to-nose测试结果在阿尔茨海默氏症和评估他们的诊断价值。背景:finger-to-nose例行测试是在患者的认知障碍的临床评估。虽然众所周知屏幕通过激活四肢的运动失调小脑功能障碍,我们发现这个测试也可以从认知的角度解释。我们描述两种典型体征观察到finger-to-nose测试在阿尔茨海默病(AD)患者:“食指综合症”和“远端压力迹象”。设计/方法:我们回顾了记录的广告(n = 365),患者血管性认知障碍(VCI;n = 40)和主观认知障碍(SCI);n = 56)在我们的记忆诊所。约80%的病人的记录包含的评级finger-to-nose测试。结果:我们发现,74%的患者显示广告认知finger-to-nose测试异常,而在SCI VCI的14%和2%(见表)。相反,VCI患者有更多的小脑测距不准(10%)比那些广告(& lt; 1%)。患者认知异常finger-to-nose测试有MMSE(20.7±5.8)显著低于那些没有(25.3±4.2;术中,0.01)。 Nevertheless, cognitive abnormality on the finger-to-nose test remained more prevalent in AD than VCI regardless of the severity, even in the earliest stages (69% in AD vs. 6% in VCI in patients with MMSE >25).Conclusions: The distal pressure and second finger signs are frequent yet unspecific findings at the finger-to-nose test in AD. Clinicoanatomical localization of these signs, and their prevalence in other neurodegenerative disorders, has to be clarified.Disclosure: Dr. Bergeron has nothing to disclose. Dr. Vermette has nothing to disclose. Dr. De La Sablonnière has nothing to disclose. Dr. Cayer has nothing to disclose. Dr. Laforce has received personal compensation for activities with Eli Lilly Canada Inc. as a member of the scientific advisory board. Dr. Bouchard has nothing to disclose. ER -